No­var­tis stakes an­oth­er PhI­II win for Cosen­tyx, goes deep­er in­to pe­di­atric mar­kets

Just hours af­ter the FDA cleared No­var­tis’ Cosen­tyx for its first pe­di­atric in­di­ca­tion, the com­pa­ny is fol­low­ing up with more pos­i­tive da­ta on an­oth­er: ju­ve­nile id­io­path­ic arthri­tis, or JIA.

The re­sults from the Phase III JU­NIPERA study, No­var­tis says, pave the way for reg­u­la­to­ry sub­mis­sions slat­ed for “the com­ing weeks,” po­ten­tial­ly carv­ing out an­oth­er big mar­ket for the top-sell­ing block­buster drug that’s fac­ing down ri­vals from every di­rec­tion in in­tense­ly com­pet­i­tive are­nas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.